(Press-News.org) Cancer remains one of the greatest health concerns in the U.S., but University of Louisville cancer researchers and UofL Health – Brown Cancer Center oncologists are improving outcomes for patients in Kentucky and beyond. UofL’s Center for Cancer Immunology and Immunotherapy (CCII), established in 2020, has been at the forefront of exciting developments in immunotherapy, using the patients’ own immune system to defeat cancer.
That work will continue and expand at UofL thanks to $11.5 million in new funding from the National Institutes of Health. The funding will support continuing research in the CCII to investigate therapies that activate the immune system against cancer and to train the next generation of cancer researchers and oncologists.
Since its launch, the CCII has helped four young researchers obtain independent federal funding and doubled the immune-oncology faculty at UofL from 10 to 20 members. The center’s faculty and research facilities also support UofL Health – Brown Cancer Center’s highly successful clinical trial program.
“The power and impact of our clinical and translational research in cancer immunotherapy are undeniable. This work provides hope for people facing a cancer diagnosis,” UofL President Gerry Bradley said. “I am grateful to our researchers and clinicians who devote their careers to advancing innovative therapies that benefit cancer patients in Kentucky and beyond and I am excited to see what the next phase brings.”
The CCII was created with an initial five-year Center of Biomedical Research Excellence (CoBRE) grant of $11.5 million in 2020. The new $11.5 million CoBRE grant announced today will support the center’s work for an additional five years.
An essential component of the CCII’s mission is translating research into the clinical realm, making UofL Health an essential part of its work. CCII supports and is supported by Brown Cancer Center.
“UofL Health – Brown Cancer Center has been developing novel immunotherapies since the early 2000s and our collaboration with UofL’s research and educational programs has translated into lives saved not only in our region but also throughout the country,” Jason Smith, chief executive officer of UofL Health, said. “This grant highlights the advantage of academic health care. We are able to leverage life-changing research from the University of Louisville and elsewhere, and put it to work to save and improve the lives of our patients.”
UofL and UofL Health – Brown Cancer Center are leaders in translating scientific discoveries to patient care and conducting clinical trials that bring new therapies to patients and improve chances of recovery for patients. Brown Cancer Center has led multiple clinical trials of tumor-infiltrating lymphocytes (TILs) therapy, and in 2024, the cellular therapy was approved by the FDA for metastatic melanoma.
“The UofL Health – Brown Cancer Center has been a leader and innovator when it comes to novel therapies like TILs,” Jason Chesney, director of Brown Cancer Center and UofL professor of medicine, said. “We started offering TILs in clinical trials back in 2016. We have seen many patients who were told elsewhere that they had no other options, but they’ve come to us, and their lives have been extended for years. This grant has allowed us to continue this research so more of our patients can make it to weddings, graduations and meet their grandchildren.”
Julie Reynolds, 69, was the first patient treated with commercial TILs for metastatic melanoma after its FDA approval in February 2024. The retired teacher and Indiana resident was treated at Brown Cancer Center with TILs therapy in June 2024 and is alive and well today.
“The clinical trials of TILs that were conducted by Dr. Chesney at UofL Health – Brown Cancer Center led to the FDA approval of TILs last year which in turn led to me being alive so that I can enjoy spending more time with my family,” Reynolds said.
Training the next generation of investigators
One key goal of CoBRE programs is to train talented young investigators to become the next generation of research leaders. At CCII, young investigators benefit from project grants and mentoring by senior investigators, supported by CoBRE funding. All four of the young investigators who led projects under the first round of center funding have now obtained major federal funding of their own, including:
Chuanlin Ding
Qingsheng Li
Corey Watson
Kavitha Yaddanapudi
“When we launched this center, our mission was ambitious: to build a vibrant community of scientists who could bridge fundamental immunology with translational and clinical research, ultimately bringing new hope to patients with cancer,” said Jun Yan, director of the CCII. “Through this next phase, we will continue to provide a nurturing environment where junior investigators can develop cutting-edge research programs, gain access to advanced technologies and receive the mentorship and resources they need to succeed.”
As a first-round project leader in the program, Yaddanapudi’s translational research supported the clinical immunotherapy program at Brown Cancer Center. She investigated immune checkpoint inhibitor resistance in lung cancer patients to improve treatment and worked with the TILs clinical trial team. Now, Yaddanapudi is a mentor for other young investigators in CCII as they build their research programs.
Junior investigators currently receiving support and training include:
Sharmila Nair
Jian Zheng
Joseph Chen
The center also houses research instruments in its Functional Immunomics Core facility. The equipment supports research by the CCII faculty, the junior researchers and other investigators at the university. It houses a Helios CyTOF instrument and a Hyperion Imaging Mass Cytometry, among other resources. To date, investigators within the program have secured approximately $33 million in research grants made possible by the core.
As part of its next phase, the CCII plans to add a tumor organoid fragment culture platform. The platform uses human tumor specimens and mimics the human body environment for more precise testing.
END
University of Louisville, UofL Health receive $11.5 million to develop new cancer immunotherapies
2025-10-22
ELSE PRESS RELEASES FROM THIS DATE:
Survey: Californians don’t know cannabis driving laws
2025-10-22
A new study from University of California San Diego has found that, while a third of Californians use cannabis regularly, there are significant gaps in knowledge around cannabis use and driving. The researchers found that even six years after the legalization of recreational cannabis use, adults in California demonstrate mixed awareness and knowledge of driving-related laws and regulations.
The study results, published in BMC Public Health, come from a large-scale survey of cannabis use in California, titled Impact 64, which was funded by the California ...
Gum disease and cavities linked to increased stroke risk
2025-10-22
EMBARGOED FOR RELEASE UNTIL 4:00 P.M. ET, WEDNESDAY, OCTOBER 22, 2025
Highlights:
A new study finds that having both gum disease and cavities is linked to an 86% increased risk of stroke compared to having a healthy mouth.
Poor oral health was tied to a 36% higher risk of heart attacks and other cardiovascular events.
People with regular dental visits were 81% less likely to have both gum disease and cavities.
Researchers say improving oral health could be an important — and often overlooked — way to help reduce stroke risk.
MINNEAPOLIS – People with both cavities and gum disease may face a higher risk of ischemic stroke, according to a study ...
Gum disease associated with changes in the brain
2025-10-22
EMBARGOED FOR RELEASE UNTIL 4:00 P.M. ET, WEDNESDAY, OCTOBER 22, 2025.
MINNEAPOLIS – Adults with gum disease may be more likely to have signs of damage to the brain’s white matter, called white matter hyperintensities, than people without gum disease, according to a new study published on October 22, 2025, in Neurology® Open Access, an official journal of the American Academy of Neurology.
White matter refers to nerve fibers that help different parts of the brain communicate. Damage to this tissue can affect memory, thinking, balance and coordination and has been linked to higher stroke risk.
White matter hyperintensities are bright spots that appear on ...
Brian Cleary awarded $2.25 million NIH grant to advance single-cell gene expression research
2025-10-22
Brian Cleary is an assistant professor in the Faculty of Computing & Data Sciences (CDS) and a core faculty member in the Bioinformatics Program. Brian also holds appointments in the Biology and Biomedical Engineering departments, and the Biological Design Center (BDC) at the Rajen Kilachand Center for Integrated Life Sciences & Engineering.
Cleary is the sole principal investigator (PI) on the five-year project, “Measuring and modeling gene expression trajectories: new computational-experimental approaches.”
The research aims to deepen understanding of how gene expression changes ...
Gut parasites identified from feces of ancient Mexican people
2025-10-22
DNA within dried feces dating from more than 1,000 years ago provides valuable insights into the pathogens that plagued ancient Mexican peoples, according to a study published October 22, 2025 in the open-access journal PLOS One by Drew Capone of Indiana University, U.S., and colleagues.
Ancient feces are a valuable source of information on the intestinal parasites of past populations. Microbial DNA is known to survive in stool samples, but analysis of ancient feces has historically been limited ...
Remission achievable for 1 in 3 Indian diabetics through intensive app-based lifestyle program
2025-10-22
Nearly one-third of people with type 2 diabetes (T2D) in an Indian cohort achieved remission through an intensive lifestyle intervention program, according to a new study publishing October 22, 2025, in the open-access journal PLOS One by Pramod Tripathi of Freedom from Diabetes Clinic & Diabetes Research Foundation, India, and colleagues.
Type 2 diabetes affects more than 72 million people in India. While lifestyle interventions have shown promise for diabetes management in Western populations, limited data exists on their effectiveness in India, where genetic and lifestyle factors place the population at higher risk.
In the new study, researchers analyzed data ...
Idiopathic hypersomnia is a rare disease of excessive sleepiness, with patients revealing they never feel rested or awake no matter how much sleep they get, in analysis of online posts
2025-10-22
Idiopathic hypersomnia is a rare disease of excessive sleepiness, with patients revealing they never feel rested or awake no matter how much sleep they get, in analysis of online posts
Article URL: http://plos.io/3KIF6W5
Article title: The experience and impact of living with idiopathic hypersomnia: A qualitative study of patient perspectives shared in online media
Author countries: U.S., Germany, Canada
Funding: This study was funded by Takeda Pharmaceuticals USA. END ...
Backyard birders in South Africa may continue to enjoy biodiversity in visiting birds under climate change scenarios, while climate change and declining biodiversity may decrease birding in protected
2025-10-22
Backyard birders in South Africa may continue to enjoy biodiversity in visiting birds under climate change scenarios, while climate change and declining biodiversity may decrease birding in protected public parks.
Article URL: https://plos.io/4ol2UxW
Article Title: Climate change impacts the non-market value of nature: A case study of birding cultural ecosystem services in South Africa
Author Countries: United States
Funding: This work was supported by the Ridge to Reef NSF Research Traineeship, Award DGE-1735040 to ...
Ingestible pill developed to diagnose intestinal disorder
2025-10-22
Researchers led by investigators at Mass General Brigham and Massachusetts Institute of Technology have validated an ingestible capsule in preclinical models for the diagnosis of acute mesenteric ischemia, a condition caused by blocked or reduced blood flow to the intestines. The research is published in Science Robotics.
Acute mesenteric ischemia accounts for less than 1.5% of emergency department visits for abdominal pain but has a mortality rate of 55%, due in part to how difficult it can be to diagnose the condition early.
“Acute mesenteric ischemia is a potentially deadly but often underdiagnosed ...
‘Chronic lung-transplant rejection has been a black box.’ New study gives answers, drug targets.
2025-10-22
Study found which abnormal cells talk to each other in harmful ways and perpetuate lung damage
Scientists are already exploring therapeutic strategies based on this study’s discoveries
Treatments also could help patients with other lung-scarring diseases (COPD, COVID-19, etc.)
CHICAGO --- More than 50% of lung-transplant recipients experience a rejection of their new lung within five years of receiving it, yet the reason why this is such a prevalent complication has remained a medical mystery.
Now, a new Northwestern Medicine study has found that, following transplant and in chronic disease states, abnormal cells emerge and “conversations” ...